Shares of Enzymotec Ltd. (NASDAQ:ENZY) have earned a consensus broker rating score of 3.33 (Hold) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a sell recommendation and two have assigned a hold recommendation to the company.

Analysts have set a 12 month consensus price target of $9.33 for the company and are anticipating that the company will post $0.10 EPS for the current quarter, according to Zacks. Zacks has also assigned Enzymotec an industry rank of 175 out of 265 based on the ratings given to related companies.

A number of research analysts have recently commented on the company. ValuEngine upgraded Enzymotec from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Zacks Investment Research cut Enzymotec from a “hold” rating to a “sell” rating in a research note on Monday, May 22nd.

ILLEGAL ACTIVITY WARNING: This story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/08/30/zacks-enzymotec-ltd-enzy-receives-average-rating-of-hold-from-analysts.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in ENZY. Acadian Asset Management LLC raised its position in shares of Enzymotec by 3.2% in the first quarter. Acadian Asset Management LLC now owns 237,184 shares of the biotechnology company’s stock valued at $2,088,000 after buying an additional 7,322 shares in the last quarter. State of New Jersey Common Pension Fund D raised its position in shares of Enzymotec by 12.5% in the first quarter. State of New Jersey Common Pension Fund D now owns 28,110 shares of the biotechnology company’s stock valued at $247,000 after buying an additional 3,113 shares in the last quarter. Janus Henderson Group PLC bought a new position in shares of Enzymotec during the second quarter valued at about $2,350,000. Finally, State Street Corp raised its position in shares of Enzymotec by 1.8% in the second quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock valued at $169,000 after buying an additional 380 shares in the last quarter. 27.92% of the stock is owned by institutional investors and hedge funds.

Shares of Enzymotec (NASDAQ:ENZY) traded down 0.44% during trading on Friday, hitting $11.40. 45,564 shares of the stock were exchanged. The stock’s market cap is $261.62 million. The stock’s 50 day moving average price is $8.98 and its 200 day moving average price is $8.65. Enzymotec has a one year low of $5.20 and a one year high of $12.35.

Enzymotec (NASDAQ:ENZY) last announced its quarterly earnings results on Wednesday, August 16th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Zacks’ consensus estimate of $0.05 by $0.15. Enzymotec had a negative net margin of 14.52% and a negative return on equity of 3.88%. The firm had revenue of $13 million during the quarter, compared to the consensus estimate of $12.78 million. During the same quarter in the previous year, the company posted $0.04 earnings per share. The firm’s revenue was up 11.1% on a year-over-year basis. Equities research analysts predict that Enzymotec will post $0.14 EPS for the current year.

About Enzymotec

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Get a free copy of the Zacks research report on Enzymotec (ENZY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related stocks with our FREE daily email newsletter.